ASH Clinical News July 2015_updated | Page 67

FEATURE Decoding Genomic Profiling G enetic assays, new sequencing platforms, and growing evidence about the role mutations play in malignancies and cancer risk have given hematologists and oncologists more information to work with than ever before, but are they actually leading to better patient care? While genomic profiling can be a valuable tool for some patients, experts say it isn’t without its pitfalls. “The hype surrounding genomic profiling is really problematic,” said Wylie Burke, MD, PhD, a professor of bioethics and humanities at the University of Washington in Seattle. “The genome has been presented to the public as ‘Your Instruction Manual’ that will tell you what to worry about and what not to worry about.” Armed with enough genetic information, it seems, a person can make the necessary adjustments to reduce his or her risk of developing a condition. “That’s erroneous, in a fundamental way.” ASH Clinical News recently spoke with Dr. Burke and other experts in the field of genomic profiling to learn about the value of genomic profiling and genetic sequencing, as well as their limitations and potential pitfalls as researchers push to move genetic findings out of the laboratory and into the clinic. Too Much Information, or Too Little? There is no shortage of researchers working to find new ways to put genetic information into practice – from characterizing a patient’s genetic risk for later developing a disease to uncovering the genetic makeup of existing tumors to guide treatment and find new therapeutic targets based on patients’ genomes. Great strides have already been made in this field, with the discovery of a slew of inherited and somatic genetic variations that contribute to the predisposition, disease progression, and treatment of a variety of hematologic malignancies. A genetic basis to other non-malignant hematologic disorders has also been uncovered, including bone marrow failure syndromes, some forms of hemoglobinopathies, and severe congenital neutropenia. There are still unanswered questions about how much these discoveries are impacting patie